The Chemotherapy Foundation is a not-for-profit public foundation uniquely dedicated to the control, cure, and prevention of cancer through innovative medical therapies – including chemotherapy, chemoimmunotherapy, chemohormonal therapy, chemoprevention, targeted therapies, and biotechnologies – and to the special education of physicians through symposia.
Foundation activities began in 1968 with the establishment of a Division of Medical Oncology in the Department of Medicine at the Mount Sinai School of Medicine. This was followed by the Chemotherapy Foundation Laboratory, built in 1970, which has remained at the core of the Foundation’s expanded research grant program. Rebuilt in 1989 and relocated to larger facilities in 2004, the Rochelle Belfer Chemotherapy Foundation Laboratory in the Division of Hematology and Medical Oncology is an acknowledged research center for the development of differentiation therapy, which studies focus on reversing the behavior of cancer cells into mature, functioning cells and programming their death.
The Foundation’s current research grant program includes additional support for selected projects in other Divisions at the now Icahn School of Medicine at Mount Sinai and research initiatives at three other major New York City cancer centers. Studies and location of Foundation grantees are summarized in our booklet Meet Our Research Grant Recipients. Some major research achievements that have contributed to progress in cancer control, specifically those inspired and supported initially by funding from The Chemotherapy Foundation, are presented in our publication Major Research Achievements of The Chemotherapy Foundation Grant Programs. (Both booklets featured in Research Programs section.)
The Foundation has remained dedicated to providing crucial seed money to gifted researchers to start groundbreaking work aimed at a specific therapeutic goal. This program is unique in that it allows synergy between basic research and clinical science. What makes this important is that, historically, key moments of real medical progress occur at the juncture of science and patient care.
For over 30 years sponsoring a Continuing Education Program for professionals, the Foundation became a vital link in keeping medical oncologists and other health professionals informed of new drugs, current trials, new modalities, and management-specific applications to benefit the patient in the physician’s office. Our annual three-day Chemotherapy Foundation Symposium - Innovative Cancer Therapy for Tomorrow is a world-class event, featuring a distinguished international faculty of over one hundred scientists, investigators and clinicians, and attracts an audience of over 1,800 clinical oncologists and cancer care professionals from the U.S. and abroad. Our 33rd Symposium (2015) and 34th Symposium (2016) have been managed by Physicians’ Education Resource, LLC (PER Events, LLC). Our 35th Symposium, from November 8-10, 2017 at the New York Marriott Marquis will, again, be hosted by PER, with our Medical Directors remaining involved in developing its scientific program. (See CFS Symposium section for program details.)
Combining rigorous chemotherapy research with professional education and implementation, the Foundation’s programs are widely recognized in the field for their significant contributions to improved patient-care management and survival.
Continuing contributions from the public, business community, and the profession are vital to expand the range and reach of these essential programs.
The Chemotherapy Foundation is a 501(c)(3) not-for-profit charitable, educational,
scientific organization and your gift is tax deductible to the extent allowable by law.